| Identification | Back Directory | [Name]
Unii-33o78xf0bw | [CAS]
635728-49-3 | [Synonyms]
Unii-33o78xf0bw
Darunavir ethanolate
[14C]-Darunavir ethanolate
Darunavir Ethanolate(Prezista)
Darunavir(TMC-114,UIC 94017) Ethanolate
DARUNAVIR ETHANOLATE (TMC114 ETHANOLATE)
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate compound with ethanol (1:1)
N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester compd. with ethanol
Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3R,3as,6ar)-hexahydrofuro(2,3-B)furan-3-yl ester, compd. with ethanol (1:1)
N-[(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl carbamic acid ester, compd. with ethanol (1:1) | [Molecular Formula]
C27H37N3O7S.C2H6O | [MDL Number]
MFCD18251642 | [MOL File]
635728-49-3.mol | [Molecular Weight]
593.732 |
| Chemical Properties | Back Directory | [Melting point ]
98-100°C | [storage temp. ]
Refrigerator | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
White |
| Hazard Information | Back Directory | [Uses]
Darunavir Ethanolate(Prezista)(635728-49-3) is an inhibitor of HIV protease. [1] Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from treatment-experienced patients with multiple resistance mutati
| [Biological Activity]
darunavir ethanolate is a nonpeptidic hiv protease inhibitor approved for the treatment of hiv infection[1].transepithelial transport of darunavir in caco-2 cell monolayers is 2-fold greater in the basal-to-apical direction compared to that in the opposite direction. in l-mdr1 cell, darunavir (121 mm) inhibits p-glycoprotein-mediated efflux of calcein-acetoxymethyl ester[1].darunavir is effective against wild-type and pi-resistant hiv, and has a low oral bioavailability (37%). when used in combination with ritonavir, bioavailability can be increased to 82%[2].[1]. fujimoto h, higuchi m, watanabe h, et al. p-glycoprotein mediates efflux transport of darunavir in human intestinal caco-2 and abcb1 gene-transfected renal llc-pk1 cell lines. biological & pharmaceutical bulletin, 2009, 32(9): 1588-1593.[2]. bhalekar mr, et al. in-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. drug deliv, 2016, 23(7): 2581-2586. | [in vivo]
Darunavir is effective against wild-type and PI-resistant HIV, and has an oral bioavailability of 37%. It needs to be combined with ritonavir, which increases the bioavailability to 82%[3]. | [IC 50]
HIV-1 | [storage]
Store at -20°C |
|
|